[1]Dimopoulos M.A., Oriol A., Nahi H. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319-1331.
[2]Dimopoulos M.A., San-Miguel J., Belch A. Daratumumab plus lenalidomide and dexamethasone lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018. versus[epub ahead of print]
[3]Kumar S., Paiva B., Anderson K.C. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328-e346.